Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.52 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.42 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.42 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 5/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.41 |
| ▸ | TYMP | P19971 | 2/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.35 |
| ▸ | MMP3 | P08254 | 1/20 | 0.35 |
| ▸ | MMP8 | P22894 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14492479 | 0.91 | NCF1 (0.45) | NCF1GNAI3GNAO1GNAI1ACHE | |
| SCHEMBL1108984 | 0.88 | — | — | |
| SCHEMBL2385657 | 0.88 | — | — | |
| SCHEMBL20095981 | 0.88 | — | — | |
| SCHEMBL28794095 | 0.88 | NCF1 (0.47) | NCF1GNAI3GNAO1GNAI1ACHE | |
| SCHEMBL1098014 | 0.86 | NCF1 (0.48) | NCF1GNAI3GNAO1GNAI1ACHE | |
| SCHEMBL1626971 | 0.84 | NCF1 (0.46) | NCF1GNAI3GNAO1GNAI1ACHE | |
| SCHEMBL24319800 | 0.84 | NCF1 (0.62) | NCF1GNAI3GNAO1GNAI1ACHE | |
| SCHEMBL245769 | 0.79 | NCF1 (0.56) | NCF1GNAI3GNAO1GNAI1ACHE | |
| SCHEMBL102678 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 933 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3157920-B1 | INDOLIZINE DERIVATIVES AS PHOSPHOINOSITIDE 3-KINASES INHIBITORS | CHIESI FARM SPA (IT) | 2019-08-07 | — | — | EP | claimed |
| EP-3157920-A1 | INDOLIZINE DERIVATIVES AS PHOSHOINOSITIDE 3-KINASES INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2017-04-26 | — | — | EP | claimed |
| US-9527869-B2 | Indolizine derivatives as phoshoinositide 3-kinases inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-12-27 | — | — | US | claimed |
| WO-2015193263-A1 | INDOLIZINE DERIVATIVES AS PHOSHOINOSITIDE 3-KINASES INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-12-23 | — | — | WO | claimed |
| US-20150361100-A1 | INDOLIZINE DERIVATIVES AS PHOSHOINOSITIDE 3-KINASES INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-12-17 | — | — | US | claimed |
| US-8815855-B2 | N-sulphonylpyrroles and their use as histone deacetylase inhibitors | 4SC AG (DE) | 2014-08-26 | — | — | US | claimed |
| EP-1802591-B1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2012-01-11 | — | — | EP | claimed |
| EP-2029580-B1 | NOVEL INDOL-PYRROL DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE AND INFLAMMATORY DISEASES | SCHEBO BIOTECH AG (DE) | 2010-06-16 | — | — | EP | claimed |
| EP-1630165-B1 | [1,2,4]TRIAZOLO[1,5-a]PYRIMIDIN-2-YLUREA DERIVATIVE AND USE THEREOF | NIPPON KAYAKU KK (JP) | 2010-03-31 | — | — | EP | claimed |
| US-20100074862-A1 | N-SULPHONYLPYRROLES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS | MAIER THOMAS | 2010-03-25 | — | — | US | claimed |
| WO-2002030926-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-04-18 | — | — | WO | claimed |
| WO-2002030924-A1 | QUINAZOLINE DERIVATIVES WITH ANTI-TUMOUR ACTIVITY | ASTRAZENECA AB (SE) | 2002-04-18 | — | — | WO | claimed |
| WO-2002016352-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-02-28 | — | — | WO | claimed |
| WO-2002002534-A1 | QUINAZOLINES WITH THERAPEUTIC USE | ASTRAZENECA AB (SE) | 2002-01-10 | — | — | WO | claimed |
| WO-2002000644-A1 | GUANIDINE DERIVATIVES OF QUINAZOLINE AND QUINOLINE FOR USE IN THE TREATMENT OF AUTOIMMUNE DISEASES | ASTRAZENECA AB (SE) | 2002-01-03 | — | — | WO | claimed |
| WO-2001094341-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF TUMOURS | ASTRAZENECA AB (SE) | 2001-12-13 | — | — | WO | claimed |
| WO-2001066099-A2 | USE OF QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | ASTRAZENECA AB (SE) | 2001-09-13 | — | — | WO | claimed |
| EP-1119567-A1 | QUINAZOLINE DERIVATIVES | AstraZeneca AB (SE) | 2001-08-01 | — | — | EP | claimed |
| WO-2001004102-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA UK LIMITED (GB) | 2001-01-18 | — | — | WO | claimed |
| WO-2000021955-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2000-04-20 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150361100-A1 | INDOLIZINE DERIVATIVES AS PHOSHOINOSITIDE 3-KINASES INHIBITORS | PIP4K2B, PIP5K1B, PIP4K2A | NCF1 1202/4885GNAI3 268/4885GNAO1 1148/4885 |
| US-20100074862-A1 | N-SULPHONYLPYRROLES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC3, HDAC2 | NCF1 1043/4885GNAI3 2478/4885GNAO1 2505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.